What's new? Log in Free sign up

Mesoblast Limited (MESO)

Company Profile

Company profile

Ticker

MESO, MEOBF

Exchange

Website

www.mesoblast.com

CEO

Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons)

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Biological Products, (No Diagnostic Substances)

Biomotion Sciences Ordinary Shares • Amgen • Gilead Sciences • Biogen • Qiagen • Sterling Check • Bio-Techne • Moderna • Acorda Therapeutics • Saratoga Investment ...

Former names

MID AMERICA APARTMENT COMMUNITIES INC

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

MESO stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Latest filings (excl ownership)

View all

Current report (foreign)

Current report (foreign)

Current report (foreign)

Current report (foreign)

Notice of effectiveness

Prospectus supplement

Shelf registration (foreign) (amended)

Shelf registration (foreign)

Current report (foreign)

Current report (foreign)

Transcripts

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

M&G INVESTMENT MANAGEMENT LTD

Financial summary

Financial statements Chart MESO financial data

Quarter (USD)	Jun 24	Jun 23	Jun 22	Jun 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Jun 24	Jun 23	Jun 22	Jun 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Institutional ownership, Q4 2024

MESO institutional ownership history Ownership history

2.8% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	65	44	+47.7%
Opened positions	27	10	+170.0%
Closed positions	6	7	-14.3%
Increased positions	20	13	+53.8%
Reduced positions	7	11	-36.4%

13F shares	Current	Prev Q	Change
Total value	59.25 bn	12.27 bn	+382.7%
Total shares	35.46 mm	33.83 mm	+4.8%
Total puts	1.10 mm	85.70 k	+1188.0%
Total calls	575.15 k	340.80 k	+68.8%
Total put/call ratio	1.9	0.3	+663.2%

Largest owners	Shares	Value	Change
George Gregory	32.28 mm	$96.69 mm	0.0%
BlackRock	727.25 k	$14.40 bn	+792.6%
MS Morgan Stanley	402.40 k	$7.97 bn	+131.8%
BAC Bank of America	290.73 k	$5.76 bn	+1503.3%
Oaktree Capital Management	179.59 k	$3.56 bn	NEW
UBS UBS	168.25 k	$3.33 bn	NEW
Susquehanna International	153.98 k	$3.05 bn	+31.9%
Summit X	145.66 k	$2.88 bn	-1.4%
Strategic Financial Concepts	138.60 k	$138.60 mm	NEW
Jane Street	102.18 k	$2.02 bn	+20.1%

Largest transactions	Shares	Bought/sold	Change
BlackRock	727.25 k	+645.77 k	+792.6%
BAC Bank of America	290.73 k	+272.60 k	+1503.3%
Group One Trading	0.00	-253.39 k	EXIT
MS Morgan Stanley	402.40 k	+228.80 k	+131.8%
Oaktree Capital Management	179.59 k	+179.59 k	NEW
UBS UBS	168.25 k	+168.25 k	NEW
Strategic Financial Concepts	138.60 k	+138.60 k	NEW
C Citigroup	100.00 k	+100.00 k	NEW
Oaktree Fund Advisors	47.91 k	+47.91 k	NEW
Citadel Advisors	0.00	-39.97 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

Reported Earlier, Mesoblast's Ryoncil Gains Spotlight At Tandem Meetings Following FDA Approval For Pediatric SR-aGvHD

Ryoncil® was approved in December 2024 by the United States Food and Drug Administration (FDA) for steroid-refractory acute graft-versus-host disease (SR-aGvHD) in pediatric patients 2 months and older, becoming the

Piper Sandler Reiterates Overweight on Mesoblast, Raises Price Target to $24

Piper Sandler analyst Edward Tenthoff reiterates Mesoblast (NASDAQ:MESO) with a Overweight and raises the price target from $15 to $24.

Top 2 Health Care Stocks That Are Ticking Portfolio Bombs

Cytek Biosciences, Emergent BioSolutions, Radiopharm Theranostics And Other Big Stocks Moving Higher On Monday

This Mesoblast Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Monday

Press releases

From Benzinga Pro

Mesoblast Sets Ryoncil® Price Based on Economic Value of Treatment With Planned Product Availability This Quarter

NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational

Mesoblast Financial Results and Corporate Update Webcast

NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and

Dr. Gregory George MD PhD Joins Mesoblast Board

NEW YORK, Feb. 23, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed Dr. Gregory George

Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now

Presenting on the Emerging Growth Conference 79 Day 1 on February 18 Register Now

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.